Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Team
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Publications/Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
  • Investors
  • Careers

Approaches to Inhibiting RAS Driven Tumors Beyond KRAS-G12C

September 16, 2020

Steve Kelsey

 

2nd Annual RAS-Targeted Drug Development Conference; September 14-16, 2020; held virtually

 

Download Presentation
Return to Media Home

Latest Publications / Presentations

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity
Approaches to Inhibiting RAS Driven Tumors Beyond KRAS-G12C
SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
Discovery and development of allosteric inhibitors of SHP2
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice
Get in touch with us